Revenue guidance for 2026 has been raised, while EBITDA pre guidance is reduced due to price pressure and regulatory changes affecting high-margin products and medical cannabis. Operational efficiency measures are underway, with further details to be shared in upcoming reports.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.